Dancann Pharma A/S

Equities

DANCAN

DK0061410487

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.056 ^DKK	-4.76%		+86.67%	+86.67%

Mar. 29	Dancann Pharma Plans Up to DKK19 Million Rights Issue	MT
Feb. 28	DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge	MT

Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025

December 20, 2023 at 03:00 am EST

Dancann Pharma A/S provided revenue guidance for the financial year 2025. For the year, the company targets a revenue growth exceeding 300%, and with that, attain the breakeven point by the year 2025.

Latest news about Dancann Pharma A/S

Dancann Pharma Plans Up to DKK19 Million Rights Issue	Mar. 29	MT
DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge	Feb. 28	MT
Dancann Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Dancann Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025	Dec. 20	CI
Dancann Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 30	CI
DanCann Pharma Issues New Shares For Debt Conversion	Nov. 23	MT
DanCann Pharma Issues New Shares Following Debt Conversion	23-10-04	MT
DanCann Pharma Issues New Shares Upon Debt Conversion	23-09-26	MT
Dancann Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
DanCann Mulls Sale of Production Facility Amid Shift in Business Strategy; Shares Plunge 13%	23-08-31	MT
DanCann Pharma Issues New Shares Upon Debt Conversion	23-08-21	MT
Dancann Pharma Lands DKK7 Million Debt Financing From Nordic Growth Fund; Shares Up 11%	23-07-18	MT
Dancann Pharma A/S' Pre-Validation Batches Meets European Standards, Paving the Path for Final Product Approval	23-06-01	CI
Dancann Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Dancann Pharma A/S Appoints Louise Bertelsen Forman as A New Additional Board Member	23-05-30	CI
Dancann Pharma Expects Final Danish Approval for Biotech Pharm1 Facility by End-summer	23-05-26	MT
Dancann Pharma in Advanced Talks for DKK12 Million Convertible Loan Deal	23-05-26	MT
Dancann Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-12	CI
Dancann Pharma A/S Auditor Raises 'Going Concern' Doubt	23-05-11	CI
DanCann Pharma to Distribute Prescription Cannabinoid-based Medications in Scandinavian Markets	23-05-09	MT
Dancann Pharma A/S Provides Positive Insight on Progress of Cannabis Bulk Product Approval	23-03-14	CI
Dancann Pharma A/S and Canngros Aps Open Office in Odense	23-02-23	CI
DanCann Pharma Hires New CFO	23-01-04	MT
DanCann Pharma A/S Appoints Peter Søndergaard as CFO	23-01-04	CI

Chart Dancann Pharma A/S

Duration

Period

More charts

Company Profile

Dancann Pharma A/S is a Denmark-based pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma manufactures and distributes prescription drugs (Rx drugs) and over-the-counter drugs (OTCs), mainly focused on pain patients with alternative needs.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DANCANN PHARMA A/S	+86.67%	1.34M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs